TL;DR — BPC-157 (Body Protection Compound 157) is a synthetic 15-amino-acid pentadecapeptide derived from a protective gastric protein. Published research has investigated its effects on tissue repair signalling, VEGF upregulation, nitric oxide pathway modulation, and gastrointestinal cytoprotection. BPC-157 is supplied strictly as a research compound for in-vitro and laboratory use. The B.A.B.E LABS range includes BPC-157 in three research blends: Wolverine, Glow Up, and The Works. Every batch is HPLC-tested to ≥99% purity with a Certificate of Analysis.
What is BPC-157?
BPC-157 — Body Protection Compound 157 — is a synthetic pentadecapeptide composed of 15 amino acids. It was first isolated and characterised from a larger gastric protective protein found in human gastric juice. The sequence is Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val.
Unlike many peptides that are fragile outside physiological conditions, BPC-157 is notable for its stability in the gastric environment — a property that has made it a subject of sustained research interest.
Mechanism of action: what the research has investigated
Published preclinical literature has explored several pathways through which BPC-157 may exert its observed effects. None of these claims are therapeutic or approved for human use; they are summarised here for the benefit of researchers designing in-vitro or animal studies.
1. VEGF and angiogenic signalling
Research has investigated BPC-157's influence on vascular endothelial growth factor (VEGF) expression and the formation of new capillary networks. Rodent studies have reported upregulation of VEGF receptor 2 (VEGFR2) and associated endothelial cell migration markers following BPC-157 administration.
Research has investigated BPC-157's influence on vascular endothelial growth factor (VEGF) expression and the formation of new capillary networks. Rodent studies have reported upregulation of VEGF receptor 2 (VEGFR2) and associated endothelial cell migration markers following BPC-157 administration.
2. Nitric oxide system modulation
Several papers have examined interactions between BPC-157 and the nitric oxide (NO) synthesis pathway. Research has suggested BPC-157 may counteract effects of both L-NAME (NO synthase inhibition) and L-arginine (NO substrate overload) — behaving as a *balancer* of NO signalling rather than a one-directional agonist or antagonist.
3. Growth hormone receptor expression
Published work has reported that BPC-157 may upregulate growth hormone receptor (GHR) expression in tendon fibroblasts. This is of particular interest for research into connective tissue recovery, and forms part of the rationale for studying BPC-157 alongside TB-500 (Thymosin Beta-4).
4. Gut–brain axis and gastrointestinal cytoprotection
Given its gastric origin, a large body of preclinical work has investigated BPC-157's effects on gastrointestinal mucosal integrity, including in models of NSAID-induced gastric damage and experimental colitis.
5. Neurological research
More recent literature has explored BPC-157 in models of traumatic brain injury, spinal cord injury, and serotonergic/dopaminergic system interaction. These remain active research areas.
Why BPC-157 is often studied with TB-500:
[TB-500 (a synthetic fragment of Thymosin Beta-4) acts through a different mechanism — primarily by regulating actin polymerisation and cell migration. Because BPC-157 and TB-500 engage distinct but complementary cellular pathways, they are frequently paired in research blends.
B.A.B.E LABS' Wolverine blend combines BPC-157 (5mg) + TB-500 (5mg) in a single vial. Glow Up adds GHK-Cu (a copper-binding tripeptide studied for skin and collagen research) to the pair. The Works adds KPV on top — a tripeptide fragment of α-MSH studied for its anti-inflammatory signalling.
Purity, testing, and Certificates of Analysis:
For research to be reproducible, the peptide under investigation must be what it claims to be. B.A.B.E LABS applies three quality controls to every BPC-157 batch:
1. HPLC (High-Performance Liquid Chromatography) — confirms the peptide content is ≥99% the target compound.
2. Mass spectrometry — verifies molecular weight matches the expected 1419.53 Da for BPC-157.
3. Certificate of Analysis (COA) — the results of both tests are documented per batch and published on the COA Page.
Before conducting research, verify purity independently where possible. Low-purity peptides introduce confounds that undermine any downstream finding.
Storage and reconstitution:
BPC-157 is supplied lyophilised (freeze-dried). Best research practice:
- Unreconstituted: store at –20°C, protected from light. Shelf-stable for 24+ months under these conditions.
- Reconstituted: add bacteriostatic water (0.9% benzyl alcohol) slowly down the inner wall of the vial. Swirl gently; do not shake. Store at 2–8°C and use within the window stated on the Certificate of Analysis.
- Avoid freeze-thaw cycles once reconstituted — these accelerate peptide degradation.
Research-use disclaimer:
All B.A.B.E LABS products, including BPC-157 blends, are supplied strictly for laboratory and in-vitro research. They are not approved by the Therapeutic Goods Administration (TGA) for human or veterinary use. They are not intended for human consumption. Buyers must be 18+ and acknowledge they are conducting legitimate research.
Where BPC-157 fits in the B.A.B.E LABS catalogue:
Suggested reading for researchers:
- Sikiric P. et al. — the foundational BPC-157 papers out of University of Zagreb explore its gastric origin and tissue-repair pharmacology.
- Reviews in Journal of Physiology – Paris and Current Pharmaceutical Design provide mechanism-focused overviews.
- For angiogenesis and VEGF pathway specifics, search PubMed for "BPC-157 VEGF" — dozens of rodent and cell-culture studies are indexed.
(Specific citations: ask for the full reference list — we maintain an internal PubMed set for researchers.)
## Frequently asked questions
**Is BPC-157 legal in Australia?**
As a research compound, BPC-157 can be purchased for in-vitro and laboratory research only. It is not TGA-approved for human therapeutic use. Buyers are responsible for compliance with Australian federal, state, and territory regulations.
**What is the difference between BPC-157 and BPC-15?**
BPC-15 is a truncated pentapeptide fragment. BPC-157 is the full 15-amino-acid pentadecapeptide and is the form most widely represented in the published literature.
**How should BPC-157 be stored after reconstitution?**
At 2–8°C (refrigerator) and used within the window stated on the COA. Avoid repeated freeze–thaw cycles.
**Why is BPC-157 so often combined with TB-500?**
They engage distinct cellular pathways — BPC-157 is associated with VEGF, NO, and GHR signalling; TB-500 with actin dynamics and cell migration. Published research has investigated their combined use for this complementarity.